Effects of Melissa officinalis L. (Lemon Balm) Extract Supplementation on Cardiovascular Risk Factors: A Pooled Analysis of Randomized Controlled Trials

Dan Liao¹, Yanyan Liu¹, Zhiwei Ouyang¹, Polin Feng¹ and Cuifen Li^1,

¹Department of Gynaecology, SSL Central Hospital of Dongguan, Affiliated Dongguan Shilong People’s Hospital of Southern Medical University, Dongguan, Guangdong, China

Cite this paper:
Dan Liao, Yanyan Liu, Zhiwei Ouyang, Polin Feng and Cuifen Li. Effects of Melissa officinalis L. (Lemon Balm) Extract Supplementation on Cardiovascular Risk Factors: A Pooled Analysis of Randomized Controlled Trials. Journal of Food and Nutrition Research. 2021; 9(7):357-362. doi: 10.12691/jfnr-9-7-5

Abstract

Several clinical trials have investigated the effects of Melissa officinalis (lemon balm) on cardiovascular risk factors, but have yielded conflicting results and had only modest sample sizes. The aim of this pool analysis was to summarize the evidence of the effects of Melissa officinalis supplementation on plasma lipid profiles, body weight, blood pressure and glucose levels. Original randomized controlled trials (RCTs) that assessed the clinical effects of Melissa officinalis consumption in human participants and published before June 2020 were identified by searching online databases, including PubMed, Scopus, Web of Science and Google Scholar databases. The quality of trials was assessed using the Cochrane Risk of Bias Tool. Quantitative data analysis was performed using weighed mean difference (WMD) and 95% confidence interval (CI) as summary statistics. Standard methods for assessing statistical heterogeneity and publication bias were used, respectively. Four trials with 244 participants were included in the final analysis. Pooling of results showed that Melissa officinalis significantly lowered total cholesterol (TC) (WMD, -7.55 mg/dL; 95% CI -14.99, -0.12; P=0.045), low-density lipoprotein cholesterol (LDL-C) (WMD, -11.33 mg/dL; 95% CI -19.46, -3.21; P=0.006), glycated hemoglobin (HbA1c) (WMD, -0.35 %; 95% CI -0.64, -0.07; P=0.01), and Systolic blood pressure (SBP) (WMD, -0.89 mmHg; 95% CI-1.69, -0.09; P=0.03). The use of Melissa officinalis did not appear to significantly alter any other study endpoints. The present findings showed that supplementation with Melissa officinalis extract were associated with a significant reduction in TC, LDL-C, HbA1c, and SBP in humans.

Keywords:
blood pressure blood glucose CVD lipid melissa officinalis

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Roth GA, Huffman MD, Moran AE, et al. Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation. 2015; 132(17): 1667-1678.
[2]	Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016; 1; 37(29): 2315-2381.
[3]	Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364(9438): 937-52.
[4]	Hong KN, Fuster V, Rosenson RS, et al. How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD. J Am Coll Cardiol. 2017; 70(17): 2171-85.
[5]	Papadogiannis DE, Protogerou AD. Blood pressure variability: a confounder and a cardiovascular risk factor. Hypertens Res. 2011; 34(2): 162-3.
[6]	Joseph JJ, Golden SH. Type 2 diabetes and cardiovascular disease: what next? Curr Opin Endocrinol Diabetes Obes. 2014; 21(2): 109-20.
[7]	Huang H, Liao D, Dong Y, et al. Effect of quercetin supplementation on plasma lipid profiles, blood pressure, and glucose levels: a systematic review and meta-analysis. Nutr Rev. 2020; 78(8): 615-626.
[8]	Huang H, Liao D, Pu R, et al. Quantifying the effects of spirulina supplementation on plasma lipid and glucose concentrations, body weight, and blood pressure. Diabetes Metab Syndr Obes. 2018; 11: 729-42.
[9]	Huang H, Liao D, Zou Y, et al. The effects of chitosan supplementation on body weight and body composition: a systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr. 2020; 60(11): 1815-1825.
[10]	Huang H, Chen G, Liao D, et al. The effects of resveratrol intervention on risk markers of cardiovascular health in overweight and obese subjects: a pooled analysis of randomized controlled trials. Obes Rev. 2016; 17(12): 1329-40.
[11]	Luís Â, Domingues F, Pereira L. Association between berries intake and cardiovascular diseases risk factors: a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials. Food Funct. 2018; 9(2): 740-57.
[12]	Shakeri A, Sahebkar A, Javadi B. Melissa officinalis L. - A review of its traditional uses, phytochemistry and pharmacology. J Ethnopharmacol. 2016; 188: 204-28.
[13]	Kwon YI, Vattem DA, Shetty K. Evaluation of clonal herbs of Lamiaceae species for management of diabetes and hypertension. Asia Pac J Clin Nutr. 2006; 15(1): 107-18.
[14]	Sobhani Z, Nami SR, Emami SA, et al. Medicinal Plants Targeting Cardiovascular Diseases in View of Avicenna. Curr Pharm Des. 2017; 23(17): 2428-43.
[15]	Javid AZ, Haybar H, Dehghan P, et al. The effects of Melissa officinalis (lemon balm) in chronic stable angina on serum biomarkers of oxidative stress, inflammation and lipid profile. Asia Pac J Clin Nutr. 2018; 27(4): 785-91.
[16]	Nayebi N, Esteghamati A, Meysamie A, et al. The effects of a Melissa officinalis L. based product on metabolic parameters in patients with type 2 diabetes mellitus: A randomized double-blinded controlled clinical trial. J Complement Integr Med. 2019; 25; 16(3).
[17]	Jandaghi P, Noroozi M, Ardalani H, et al. Lemon balm: A promising herbal therapy for patients with borderline hyperlipidemia-A randomized double-blind placebo-controlled clinical trial. Complement Ther Med. 2016; 26: 136-40.
[18]	Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009 Jul 21; 6(7): e1000100.
[19]	Willame C, Cheuvart B, Aris E, et al. Association between rotavirus gastroenteritis and intussusception: suggested evidence from a retrospective study in claims databases in the United States. Hum Vaccin Immunother. 2020; 1: 1-9.
[20]	Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003 Sep 6; 327(7414): 557-660.
[21]	Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4): 1088-101.
[22]	Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109): 629-634.
[23]	Asadi A, Shidfar F, Safari M, et al. Efficacy of Melissa officinalis L. (lemon balm) extract on glycemic control and cardiovascular risk factors in individuals with type 2 diabetes: A randomized, double-blind, clinical trial. Phytother Res. 2019; 33(3): 651-659.
[24]	Asadi A, Shidfar F, Safari M, et al. Safety and efficacy of Melissa officinalis (lemon balm) on ApoA-I, Apo B, lipid ratio and ICAM-1 in type 2 diabetes patients: A randomized, double-blinded clinical trial. Complement Ther Med. 2018; 40: 83-88.
[25]	Chung MJ, Cho SY, Bhuiyan MJ, et al. Anti-diabetic effects of lemon balm (Melissa officinalis) essential oil on glucose- and lipid-regulating enzymes in type 2 diabetic mice. Br J Nutr. 2010; 104(2): 180-188.
[26]	Jun HJ, Lee JH, Jia Y, et al. Melissa officinalis essential oil reduces plasma triglycerides in human apolipoprotein E2 transgenic mice by inhibiting sterol regulatory element-binding protein-1c-dependent fatty acid synthesis. J Nutr. 2012; 142(3): 432-440.
[27]	McCue PP, Shetty K. Inhibitory effects of rosmarinic acid extracts on porcine pancreatic amylase in vitro. Asia Pac J Clin Nutr. 2004; 13(1): 101-106.